ArticleJournal of clinical apheresis2026
Trends in Clinical Indications for Plasma Exchange in Adult Patients Between 2008 and 2024 in Bogotá, Colombia.
Article in Journal of clinical apheresis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This multicenter retrospective study aimed to describe temporal trends in clinical indications for plasma exchange (PE) in adult patients at four quaternary-care hospitals in Bogotá (2008-2024) and to examine their distribution across successive ASFA guideline editions. Adults ≥ 18 years who received ≥ 1 PE session were included; indications were coded using ICD-10, and outcomes were classified as complete improvement, partial improvement, no change, or death. Descriptive statistics were performed using RStudio. Of 970 patients screened, 758 met eligibility criteria. Median age was 47 years (IQR 33-60); 62.4% were women. Neurological and rheumatological indications predominated (n = 634, 83.6%), particularly neuromyelitis optica spectrum disorders and ANCA-associated vasculitis. A total of 3954 sessions were performed (median: 5 per patient; IQR: 5-6). Hypocalcemia was the most frequent complication. Overall, 74.0% achieved complete or partial improvement, with higher rates in neurological conditions. Sixty-nine deaths occurred (9.1%), mostly attributed to systemic autoimmune diseases. Over the study period, neuroimmunological indications increased markedly, while use of PE for ANCA-associated vasculitis declined following its reclassification to ASFA category III in 2023. ASFA categories I and II accounted for 92.7% of indications; Category I representation declined from 66.7% (2008-2010) to 40.6% (2023-2024), while case volume grew from 21 to 266 patients per triennium. Over 16 years, PE indications shifted substantially toward immune-mediated neurological disorders, driven by expanded diagnostic availability for AQP4-IgG and MOG-IgG and evolving ASFA recommendations. These findings underscore the need for prospective studies and a national PE registry in Colombia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.